BioLife Solutions, Inc. (BLFS) fair value analysis
Nasdaq · Updated 2026-09-07
BioLife Solutions, Inc. is a healthcare company that develops and manufactures biopreservation equipment and related consumables used to preserve cellular and tissue-based products for medical applications. The company operates primarily in the United States and serves customers in the regenerative medicine, cell therapy, and organ transplantation industries.
Valuation status
Awaiting full valuationBLFS does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $32.15
- Sector
- Healthcare
- 12-month range
- $19.29–$32.15
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The top quarter of its range
What our data shows for BLFS
- Shares are trading in the upper third of their 12-month price range of $19.29–$32.15.
- The 14-day relative strength index sits at a neutral 52.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BLFS
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent BLFS news
TickrTrends' derived news-sentiment signal for BLFS is currently mixed, computed from recent coverage.
- Diamond Hill Bets on BioLife Solutions’ (BLFS) High Switching Cost (finance.yahoo.com, 2026-09-04)
TickrTrends take: BioLife Solutions operates in the Healthcare sector where switching costs can represent a significant competitive moat, particularly relevant as TickrTrends awaits full valuation data for BLFS. The company's high switching costs suggest customer retention strengths that typically warrant closer examination when establishing a comprehensive valuation framework. Investors tracking BLFS should monitor how these switching dynamics translate into revenue stability and pricing power, factors that will inform the eventual valuation assessment. - BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates (zacks.com, 2026-08-06)
TickrTrends take: BioLife Solutions' better-than-expected Q2 performance provides concrete earnings data that could inform the completion of TickrTrends' full valuation assessment currently in progress. For a valuation-focused investor, the key consideration is whether this earnings beat represents sustainable operational improvement or a temporary outperformance, as this distinction will materially affect how the company's healthcare sector positioning translates into a justified valuation range. The strength of this earnings result may accelerate the depth of analysis needed to move from an awaiting status to a complete valuation verdict. - Repligen Corporation (RGEN) BioLife Solutions, Inc., - M&A Call - Slideshow (NASDAQ:RGEN) 2026-07-23 (seekingalpha.com, 2026-07-23)
TickrTrends take: BioLife Solutions operates in the Healthcare sector and is currently awaiting full valuation on TickrTrends, meaning detailed pricing metrics are still being compiled. The M&A call involving Repligen Corporation suggests potential strategic developments that could materially impact how the company should be valued going forward. Investors focused on valuation should monitor whether this transaction activity leads to updated financial guidance or changes in growth expectations that would inform a complete valuation assessment.
What people are saying
Follow the BLFS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — BLFS in the Healthcare sector showed mixed momentum shifts this week as derived indicators adjusted from prior levels. The 50/200-day trend state moved from uptrend to mixed, while the Relative Strength Index zone transitioned from overbought to neutral territory. The current valuation verdict remains awaiting full valuation.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BLFS stock undervalued?
BLFS does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is BLFS's TickrTrends verdict?
BLFS is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is BLFS overbought or oversold?
BLFS's 14-day RSI is in neutral territory - neither overbought nor oversold.